Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 4/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 2/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.30 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3610601 | 0.99 | RAD52 (0.32) | RAD52RIPK1NR1H2F11CNR2 | |
| SCHEMBL3604212 | 0.91 | NR1H2 (0.34) | RAD52NR1H2F11XIAPPPARG | |
| Hydrochloric Acid SCHEMBL3603755 | 0.90 | NR1H2 (0.34) | RAD52NR1H2F11XIAP | |
| Hydrochloric Acid SCHEMBL3607691 | 0.89 | CYP2D6 (0.33) | RIPK1F11CNR2PPARGPPARD | |
| SCHEMBL3608297 | 0.88 | RIPK1 (0.32) | RIPK1F11CNR2 | |
| Hydrochloric Acid SCHEMBL3604099 | 0.87 | F11 (0.31) | RIPK1F11CNR2 | |
| SCHEMBL3614824 | 0.87 | GHSR (0.37) | RAD52NR1H2F11XIAPPPARG | |
| SCHEMBL3613400 | 0.86 | CYP2D6 (0.31) | RIPK1F11XIAPPPARGPPARD | |
| Hydrochloric Acid SCHEMBL3608128 | 0.86 | GHSR (0.36) | RAD52NR1H2F11XIAPPPARG | |
| SCHEMBL3599877 | 0.86 | RORC (0.34) | RIPK1F11PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | claimed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | claimed |
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | RAD52 3267/4885RIPK1 4420/4885NR1H2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.